A new risk model for the evaluation of the thromboembolic milieu in patients with atrial fibrillation: the PALSE score

Elif H. Ozcan Cetin¹, Mustafa B. Ozbay¹, Mehmet S. Cetin², Hasan C. Könte¹,
Nezaket M. Yaman¹, Bahar T. Tak¹, Firdevs A. Ekizler¹, Fırat Ozcan¹ Ozcak Ozeke¹,
Serkan Cay¹, Burak Akçay¹, Omac Tufekcióglu¹, Serkan Topaloglu¹, Dursun Aras¹

1 Cardiology Department, Ankara City Hospital, Ankara, Turkey
2 Cardiology Clinic, Etimesgut State Hospital, Ankara, Turkey

KEY WORDS
atrial fibrillation, left atrial thrombus, spontaneous echo contrast, thromboembolic milieu

ABSTRACT
BACKGROUND The evaluation of thromboembolic risk is the cornerstone of atrial fibrillation (AF) management. Thromboembolic risk is associated with the presence of left atrial (LA) thrombus and spontaneous echo contrast (SEC), namely the thromboembolic milieu.
AIMS We aimed to assess the predictors of the thromboembolic milieu in terms of LA thrombus and / or SEC in patients with paroxysmal AF undergoing electrical cardioversion or catheter ablation, and to develop an effective risk model for detecting the thromboembolic milieu.
METHODS We included a total of 434 patients with nonvalvular paroxysmal AF who underwent transesophageal echocardiography prior to cardioversion or catheter ablation.
RESULTS In patients with the thromboembolic milieu, total protein and C-reactive protein levels, LA diameter, and systolic pulmonary artery pressure (SPAP) were higher, while left ventricular ejection fraction (LVEF) was lower than in patients without the thromboembolic milieu. In a multivariate logistic regression analysis, age, total protein levels, LVEF, LA diameter, and SPAP were independent predictors of LA thrombus and / or SEC. In a receiver operating characteristic curve analysis, the optimal cutoff values for the discrimination of patients with the thromboembolic milieu were as follows: 60 years for age; 7.3 mg/dl for total protein; 40% for LVEF; 40 mm for LA diameter; and 35 mm Hg for SPAP. Based on these cutoff values, we developed a novel risk model, namely, the PALSE score. The area under the curve for the PALSE score was 0.833. Patients with a PALSE score lower than 1 did not show thrombus or spontaneous echo contrast.
CONCLUSIONS The PALSE score, which includes total protein levels, age, LA diameter, SPAP, and LVEF, seemed to accurately predict the presence of the thromboembolic milieu in patients with paroxysmal AF.

INTRODUCTION Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice, and its thromboembolic complications can cause significant morbidity and mortality. Together with LA thrombus, moderate or severe SEC forms the thromboembolic milieu. Routine identification of LA thrombus and / or SEC is generally difficult, as it requires semi-invasive procedures, such as transesophageal echocardiography (TEE). The current guidelines on the management of AF recommend the CHA₂DS₂-VASc score (congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke...
WHAT’S NEW?
In our study, we found that age, left atrial diameter, systolic pulmonary artery pressure, left ventricular ejection fraction, and total protein levels were independent predictors of left atrial (LA) thrombus and/or spontaneous echo contrast (SEC) in patients with paroxysmal atrial fibrillation undergoing transesophageal echocardiography prior to cardioversion or catheter ablation. We determined the optimal cutoff values for these parameters and developed a novel risk score (PALSE), which was shown to accurately predict the presence of the thromboembolic milieu. In patients with a PALSE score lower than 1, neither thrombus nor spontaneous echo contrast were found. The PALSE score may facilitate a more comprehensive management of patients with atrial fibrillation.

METHODS Patient selection and study design
We examined the records of 698 consecutive patients with nonvalvular paroxysmal AF who underwent TEE prior to electrical cardioversion or catheter ablation between January 2012 and January 2019. Patients with valvular AF (moderate-to-severe mitral valve stenosis and prosthetic heart valves), congenital heart diseases, malignancy, inflammatory and autoimmune diseases, or renal insufficiency requiring dialysis were excluded from the study.

Hypertension was defined as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or the use of antihypertensive drugs. Diabetes was defined as fasting blood glucose levels higher than 126 mg/dl or the use of antidiabetic drugs. Hyperlipidemia was defined as total cholesterol levels higher than 200 mg/dl, low-density lipoprotein levels higher than 130 mg/dl, triglyceride levels higher than 150 mg/dl, or the use of lipid-lowering drugs. Coronary artery disease (CAD) was defined as a history of percutaneous or surgical coronary interventions or the presence of a minimum of 50% stenosis in at least 1 of the main coronary arteries. In each patient, a history of ischemic stroke and transient ischemic attack was recorded and the CHA2DS2-VASc score was calculated. The study protocol was approved by the institutional review board and written informed consent was obtained from all participants.

Echocardiographic data All participants underwent transthoracic echocardiography and TEE using Vivid 7 Pro (GE Vingmed Ultrasound, Horten, Norway). All echocardiographic examinations were performed according to the recommendations of the American Society of Echocardiography.12-15 Left ventricular ejection fraction (LVEF) was measured with the modified Simpson technique. Left ventricular end-diastolic diameter (LVEDD), LA diameter, and systolic pulmonary artery pressure (SPAP) were recorded. All TEE examinations were performed by experienced echocardiographers (OT and ÖÖ) in our echocardiography laboratory. The LA appendage (LAA) was assessed in the midesophageal 4-chamber view at 0º and then by rotating the multiplane angle to 30º, 60º, 90º, and 180º, so as not to overlook thrombus or SEC. The diagnosis of LA thrombus was confirmed by the presence of an echodense mass in the LA or LAA. Mild SEC was identified as minimal echogenicity in the LAA or sparsely distributed in the LA. Malignant SEC was defined as a dense swirling pattern in the LA or LAA (or both), which is usually associated with slightly lower intensity in the main cavity and which may fluctuate in intensity but is detectable constantly throughout the cardiac cycle. Severe SEC was defined as intense echo density and a very slow swirling pattern in the LA or LAA (or both), with a similar density as in the main cavity.16 Patients with LA thrombus or moderate or severe SEC (or both) were classified as the group with the thromboembolic milieu.

Blood sampling Peripheral venous blood was taken from the antecubital vein after a 12-hour overnight fast and collected into yellow tubes without an anticoagulant for biochemical parameters were measured using an automated hematologic analyzer XE-1200 (Sysmex, Kobe, Japan). Other biochemical parameters were measured using a molecular analyzer (Roche Diagnostics, Manheim, Germany).

Statistical analysis Continuous data were reported as the median (interquartile range) or mean (SD). The Kolmogorov–Smirnov test was used to assess the distribution pattern. Categorical variables were reported as the number and percentage. Comparisons between the 2 groups were performed with the t test for normally distributed variables and the χ² test or Fisher exact test for categorical variables. A univariate analysis was used to assess the effects of different variables on the occurrence of the thromboembolic milieu and determine the variables with an unadjusted P value of less than 0.1 as potential risk markers. We developed the final model.
In a univariate regression analysis, age, CAD, CHA2DS2VASc score, glucose, urea, creatinine, total protein, and C-reactive protein levels, LVEF, LVEDD, LA diameter, and SPAP were associated with the presence of the thromboembolic milieu. After adjustment for other parameters, age, total protein, LVEF, LA diameter, and SPAP were determined to be independent predictors of the thromboembolic milieu (Table 3).

In the ROC curve analysis, the optimal cutoff values for the discrimination of cases with the thromboembolic milieu were as follows: 60 years for age; 7.3 mg/dl for total protein levels; 40% for LVEF; 40 mm for LA diameter; and 35 mm Hg for SPAP. Detailed data are presented in Figure 1. Based on these cutoff values, we developed a risk model, namely, the PALSE score. The ROC curve demonstrating the discriminatory value of the PALSE score for the thromboembolic milieu is presented in Figure 2. Additionally, the PALSE score predicted LA thrombus (Figure 3A) and moderate or severe SEC (Figure 3B).

Of the 259 patients with a CHA2DS2VASc score lower than 2, 24 patients (9.3%) had the thromboembolic milieu (thrombus in 12 patients [4.6%] and moderate or severe SEC in 17 patients [6.6%]). Patients with a PALSE score lower than 1 showed neither thrombus nor SEC.

By using backward elimination for a multivariate logistic regression analysis. After the multivariate analysis, we created the receiver operating characteristic (ROC) curve models to determine the individual optimal cutoff values. Then, we graded the independent variables in a binary fashion according to the cutoff values (1 point meant above the cutoff, otherwise 0). To evaluate the presence of the thromboembolic milieu, we generated a novel risk score with these cutoff values. The overall discriminative performance of this novel risk score was also assessed in the ROC curve analysis. In all analyses, a P value of less than 0.05 was considered significant. The SPSS 20.0 software (SPSS, Inc., Chicago, Illinois, United States) was used for statistical analysis.

**RESULTS** The study included 434 patients. Patients with the thromboembolic milieu more often had CAD and a CHA2DS2VASc of 2 or higher that those without the thromboembolic milieu (Table 1). They were also older and had higher urea, creatinine, total protein, and C-reactive protein levels. Moreover, they had greater LVEDD and LA diameters, higher SPAP levels, and lower LVEF than the group without the thromboembolic milieu (Table 2).

**TABLE 1** Baseline clinical characteristics of the study groups

| Parameter                | Total   | Patients without thromboembolic milieu | Patients with thromboembolic milieu | P value |
|--------------------------|---------|----------------------------------------|-------------------------------------|---------|
| Age, y, mean (SD)        | 55.5 (12)| 54.7 (12.2)                            | 61.2 (8.8)                          | <0.001  |
| Male sex                 | 242 (55.8)| 212 (55.5)                            | 30 (57.7)                           | 0.77    |
| Hypertension             | 162 (37.3)| 138 (36.1)                            | 24 (46.2)                           | 0.16    |
| Diabetes                 | 46 (10.6)| 37 (9.7)                               | 9 (17.3)                            | 0.09    |
| CAD                      | 60 (13.8)| 48 (12.6)                               | 12 (23.1)                           | 0.04    |
| Stroke/TIA               | 7 (1.6)| 5 (1.3)                                 | 2 (3.8)                             | 0.17    |
| History of MI            | 19 (4.4)| 3 (5.8)                                 | 16 (4.2)                            | 0.53    |
| CHA2DS2VASc ≥2           | 259 (59.7)| 235 (61.5)                            | 24 (46.2)                           | 0.03    |
| ASA                      | 62 (14.3)| 49 (12.8)                               | 13 (25)                             | 0.02    |
| Clopidogrel              | 17 (3.9)| 15 (3.9)                               | 2 (3.8)                             | 0.98    |
| Anticoagulant therapy    | 175 (40.3)| 147 (38.5)                            | 28 (53.8)                           | 0.03    |
| NOAC                     | 80 (18.4)| 67 (17.5)                               | 13 (25)                             | 0.19    |
| Dabigatran               | 16 (3.7)| 14 (3.7)                               | 2 (3.8)                             | 0.95    |
| Rivaroxaban              | 25 (5.8)| 21 (5.5)                               | 4 (7.7)                             | 0.52    |
| Apixaban                 | 33 (7.6)| 27 (7.1)                               | 6 (11.5)                            | 0.25    |
| Edoxaban                 | 6 (1.4)| 5 (1.3)                                 | 1 (1.9)                             | 0.72    |
| Warfarin                 | 95 (21.9)| 80 (20.9)                               | 15 (28.8)                           | 0.2     |

Data are presented as number (percentage) of patients unless otherwise indicated.

Abbreviations: ASA, acetylsalicylic acid; CAD, coronary artery disease; CHA2DS2VASc, congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or thromboembolism, vascular disease, age of 65 to 74 years, female sex; LA, left atrial; MI, myocardial infarction; NOAC, non–vitamin K antagonist oral anticoagulant; TIA, transient ischemic attack.
Table 2
Baseline laboratory and echocardiographic findings in the study groups

| Parameter                        | Total Patients without thromboembolic milieu | Patients with thromboembolic milieu | P value  |
|----------------------------------|---------------------------------------------|-------------------------------------|----------|
| Glucose, mg/dl                  | 101.2 (27.2)                                | 100.4 (25.8)                        | 107.2 (35.4) | 0.09 |
| Urea, mg/dl                     | 31.0 (8.5)                                  | 30.5 (7.7)                          | 34.8 (12.8) | <0.001 |
| Creatinine, mg/dl               | 0.9 (0.2)                                   | 0.9 (0.2)                           | 1 (0.3)    | 0.03  |
| Uric acid, mg/dl                | 6.2 (4.2)                                   | 6.3 (4.3)                           | 6.3 (3.3)  | 0.11  |
| AST, U/l, median (IQR)          | 20 (15–26)                                  | 20 (15–26)                          | 19.5 (15–26.3) | 0.85 |
| ALT, U/l, median (IQR)          | 21.3 (14–32)                                | 21.6 (14–32)                        | 20.1 (13.3–29.3) | 0.45 |
| Albumin, mg/dl                  | 4.2 (0.3)                                   | 4.2 (0.3)                           | 4.3 (0.3)  | 0.19  |
| Total protein, mg/dl            | 7.1 (0.5)                                   | 7.1 (0.5)                           | 7.4 (0.5)  | <0.001 |
| LDL cholesterol, mg/dl          | 100.3 (31.1)                                | 100.3 (30.2)                        | 100.2 (37.6) | 0.99 |
| Hemoglobin, mg/dl               | 14.1 (1.6)                                  | 14.1 (1.6)                          | 14.2 (1.5) | 0.78  |
| Hematocrit, %                   | 43.2 (4.1)                                  | 43.1 (4.1)                          | 43.7 (4.1) | 0.35  |
| WBC, × 10⁹/µl                   | 7.4 (3.3)                                   | 7.4 (3.5)                           | 7.6 (1.8)  | 0.69  |
| Neutrophils, × 10⁹/µl           | 4.5 (1.4)                                   | 4.5 (1.4)                           | 4.6 (1.5)  | 0.59  |
| Lymphocytes, × 10⁹/µl           | 2.4 (0.9)                                   | 2.4 (0.9)                           | 2.2 (0.8)  | 0.55  |
| CRP, mg/l, median (IQR)         | 1.3 (0.9–3.4)                               | 1.2 (0.9–3.2)                       | 3.1 (1.1–4.9) | <0.001 |
| LVEF, %                         | 58.4 (7.2)                                  | 59.2 (6)                            | 52.8 (11.5) | <0.001 |
| LVEDD, mm                       | 46.6 (3.7)                                  | 46.4 (3.4)                          | 48.4 (4.9) | 0.001 |
| LA diameter, mm                 | 38.6 (5.2)                                  | 38.1 (4.9)                          | 42.6 (5.1) | <0.001 |
| SPAP, mm Hg                     | 30.3 (7)                                    | 29.4 (6.1)                          | 37.3 (9.1) | <0.001 |

Data are presented as mean (SD) unless otherwise indicated.

SI conversion factors: to convert C-reactive protein to nmol/l, multiply by 9.524; glucose to mmol/l, by 0.0555, LDL cholesterol to mmol/l, multiply by 0.0259.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; HDL, high-density lipoprotein; IQR, interquartile range; LA, left atrium; LDL, low-density lipoprotein; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; SPAP, systolic pulmonary artery pressure; WBC, white blood cell; others, see Table 1

Table 3
Predictors of the thromboembolic milieu in univariate and multivariate regression analyses (continued on the next page)

| Parameter        | Univariate analysis, OR (95% CI) | P value  | Multivariate analysis, OR (95% CI) | P value  |
|------------------|----------------------------------|----------|------------------------------------|----------|
| Age, y           | 1.055 (1.024–1.086)              | <0.001   | 1.044 (1.010–1.079)                | 0.01     |
| Female sex       | 1.093 (0.609–1.965)              | 0.77     | –                                  | –        |
| Hypertension     | 1.516 (0.845–2.717)              | 0.16     | –                                  | –        |
| Diabetes         | 1.952 (0.882–4.319)              | 0.1      | –                                  | –        |
| Stroke / TIA     | 3.016 (0.570–15.960)             | 0.19     | –                                  | –        |
| CAD              | 2.087 (1.024–4.257)              | 0.04     | –                                  | –        |
| CHA2DS2VASc      | 1.865 (1.041–3.341)              | 0.04     | –                                  | –        |
| Glucose          | 1.007 (0.999–1.016)              | 0.1      | –                                  | –        |
| Urea             | 1.050 (1.018–1.083)              | 0.002    | –                                  | –        |
| Creatinine       | 3.750 (1.101–12.771)             | 0.04     | –                                  | –        |
| Uric acid        | 0.940 (0.872–1.014)              | 0.11     | –                                  | –        |
| AST              | 1.012 (0.990–1.034)              | 0.3      | –                                  | –        |
Table 3  Predictors of the thromboembolic milieu in univariate and multivariate regression analyses (continued from the previous page)

| Parameter          | Univariate analysis, OR (95% CI) | P value | Multivariate analysis, OR (95% CI) | P value |
|--------------------|----------------------------------|---------|------------------------------------|---------|
| ALT                | 0.987 (0.970–1.005)              | 0.16    | –                                  | –       |
| Albumin            | 1.972 (0.709–5.487)              | 0.19    | –                                  | –       |
| Total protein      | 4.326 (2.168–8.633)              | <0.001  | 4.234 (1.911–9.386)                | <0.001  |
| LDL cholesterol    | 1.000 (0.991–1.009)              | 0.97    | –                                  | –       |
| Hemoglobin         | 1.028 (0.851–1.241)              | 0.78    | –                                  | –       |
| Hematocrit         | 1.035 (0.962–1.113)              | 0.35    | –                                  | –       |
| WBC                | 1.015 (0.943–1.092)              | 0.69    | –                                  | –       |
| Neutrophils        | 1.056 (0.866–1.287)              | 0.59    | –                                  | –       |
| Lymphocytes        | 0.923 (0.730–1.168)              | 0.5     | –                                  | –       |
| CRP                | 1.102 (1.017–1.194)              | 0.02    | –                                  | –       |
| LVEF               | 0.918 (0.886–0.948)              | <0.001  | 0.954 (0.919–0.991)                | 0.02    |
| LVEDD              | 1.131 (1.050–1.218)              | 0.001   | –                                  | –       |
| LA diameter        | 1.148 (1.087–1.212)              | <0.001  | 1.080 (1.013–1.151)                | 0.02    |
| SPAP               | 1.139 (1.094–1.186)              | <0.001  | 1.087 (1.036–1.140)                | 0.001   |

Abbreviations: OR, odds ratio; others, see TABLES 2 and 3

Figure 1  Receiver operating characteristic curves demonstrating the discriminatory power of total protein levels (A), age (B), left atrial diameter (C), systolic pulmonary artery pressure (D), and left ventricular ejection fraction (E) for the thromboembolic milieu

Abbreviations: AUC, area under the curve
The PALSE score and thromboembolic milieu

ORIGINAL ARTICLE

The prediction of the thromboembolic milieu may provide additional information beyond traditional risk scores in the evaluation of the thromboembolic risk in patients with AF. Left atrial thrombus and SEC are well-known manifestations of the thromboembolic milieu in AF patients. They are caused by different pathological conditions and interrelated anatomical, hemodynamic, and biological factors, such as decreased blood flow velocity as well as increased blood viscosity and coagulopathy. Therefore, the evaluation of the thromboembolic risk should account for all these conditions in a more comprehensive manner.

In contrast to traditional risk scores depending on the cumulative thromboembolic risk, those depending on the presence of the thromboembolic milieu may provide better identification of high-risk patients. Current literature routinely used in decision-making concerning anticoagulant therapy. However, in the setting of the thromboembolic milieu, these risk scores seem to provide controversial data, which precludes their routine use. The prediction of the thromboembolic milieu may provide additional information beyond traditional risk scores in the evaluation of the thromboembolic risk in patients with AF.

In our study, we found that total protein levels, LA diameter, SPAP, age, as well as LVEF were independent predictors of the thromboembolic milieu in patients with paroxysmal AF undergoing cardioversion or catheter ablation. We also determined the optimal cutoff values for these parameters and developed a novel risk model, namely, the PALSE score, which was shown to accurately predict the presence of LAT. Besides, the PALSE score was shown to accurately predict the presence of LA thrombus and SEC both in combination or separately. Patients with a PALSE score lower than 1 did not have thrombus or SEC on TEE. In contrast, CHA₂DS₂VASc did not demonstrate satisfactory results in terms of predicting the thromboembolic milieu.

The PALSE score was shown to accurately predict the presence of LAT. The AUC for the PALSE score was 0.833 (95% CI, 0.744–0.891; P < 0.001). The sensitivity and specificity at the optimal cutoff value were 78% and 90%, respectively. The sensitivity, specificity, and AUC of CHA₂DS₂VASc for predicting LAT were 68%, 90%, and 0.78, respectively.

In current practice, clinical risk scores such as CHADS₂ (congestive heart failure, hypertension, diabetes, age ≥75 years, history of stroke or transient ischemic attack) and its more comprehensive variant, CHA₂DS₂VASc, predict the 1-year thromboembolic risk and are routinely used in decision-making concerning anticoagulant therapy. However, in the setting of the thromboembolic milieu, these risk scores seem to provide controversial data, which precludes their routine use. The prediction of the thromboembolic milieu may provide additional information beyond traditional risk scores in the evaluation of the thromboembolic risk in patients with AF.

In our study, we found that total protein levels, LA diameter, SPAP, age, as well as LVEF were independent predictors of the thromboembolic milieu in patients with paroxysmal AF undergoing cardioversion or catheter ablation. We also determined the optimal cutoff values for these parameters and developed a novel risk model, namely, the PALSE score, which was shown to accurately predict the presence of LAT. Besides, the PALSE score was shown to accurately predict the presence of LA thrombus and SEC both in combination or separately. Patients with a PALSE score lower than 1 did not have thrombus or SEC on TEE. In contrast, CHA₂DS₂VASc did not demonstrate satisfactory results in terms of predicting the thromboembolic milieu.

The PALSE score was shown to accurately predict the presence of LAT. The AUC for the PALSE score was 0.833 (95% CI, 0.744–0.891; P < 0.001). The sensitivity and specificity at the optimal cutoff value were 78% and 90%, respectively. The sensitivity, specificity, and AUC of CHA₂DS₂VASc for predicting LAT were 68%, 90%, and 0.78, respectively.

DISCUSSION

In our study, we found that total protein levels, LA diameter, SPAP, age, as well as LVEF were independent predictors of the thromboembolic milieu in patients with paroxysmal AF undergoing cardioversion or catheter ablation. We also determined the optimal cutoff values for these parameters and developed a novel risk model, namely, the PALSE score, which was shown to accurately predict the presence of LAT. Besides, the PALSE score was shown to accurately predict the presence of LA thrombus and SEC both in combination or separately. Patients with a PALSE score lower than 1 did not have thrombus or SEC on TEE. In contrast, CHA₂DS₂VASc did not demonstrate satisfactory results in terms of predicting the thromboembolic milieu.

The evaluation of the thromboembolic risk in AF remains the cornerstone of patient management. In current practice, clinical risk scores such as CHADS₂ (congestive heart failure, hypertension, diabetes, age ≥75 years, history of stroke or transient ischemic attack) and its more comprehensive variant, CHA₂DS₂VASc, predict the 1-year thromboembolic risk and are routinely used in decision-making concerning anticoagulant therapy. However, in the setting of the thromboembolic milieu, these risk scores seem to provide controversial data, which precludes their routine use. The prediction of the thromboembolic milieu may provide additional information beyond traditional risk scores in the evaluation of the thromboembolic risk in patients with AF.

Left atrial thrombus and SEC are well-known manifestations of the thromboembolic milieu in AF patients. They are caused by different pathological conditions and interrelated anatomical, hemodynamic, and biological factors, such as decreased blood flow velocity as well as increased blood viscosity and coagulopathy. Therefore, the evaluation of the thromboembolic risk should account for all these conditions in a more comprehensive manner.

In contrast to traditional risk scores depending on the cumulative thromboembolic risk, those depending on the presence of the thromboembolic milieu may provide better identification of high-risk patients. Current literature routinely used in decision-making concerning anticoagulant therapy. However, in the setting of the thromboembolic milieu, these risk scores seem to provide controversial data, which precludes their routine use. The prediction of the thromboembolic milieu may provide additional information beyond traditional risk scores in the evaluation of the thromboembolic risk in patients with AF.

In our study, we found that total protein levels, LA diameter, SPAP, age, as well as LVEF were independent predictors of the thromboembolic milieu in patients with paroxysmal AF undergoing cardioversion or catheter ablation. We also determined the optimal cutoff values for these parameters and developed a novel risk model, namely, the PALSE score, which was shown to accurately predict the presence of LAT. Besides, the PALSE score was shown to accurately predict the presence of LA thrombus and SEC both in combination or separately. Patients with a PALSE score lower than 1 did not have thrombus or SEC on TEE. In contrast, CHA₂DS₂VASc did not demonstrate satisfactory results in terms of predicting the thromboembolic milieu.

The PALSE score was shown to accurately predict the presence of LAT. The AUC for the PALSE score was 0.833 (95% CI, 0.744–0.891; P < 0.001). The sensitivity and specificity at the optimal cutoff value were 78% and 90%, respectively. The sensitivity, specificity, and AUC of CHA₂DS₂VASc for predicting LAT were 68%, 90%, and 0.78, respectively.

DISCUSSION

In our study, we found that total protein levels, LA diameter, SPAP, age, as well as LVEF were independent predictors of the thromboembolic milieu in patients with paroxysmal AF undergoing cardioversion or catheter ablation. We also determined the optimal cutoff values for these parameters and developed a novel risk model, namely, the PALSE score, which was shown to accurately predict the presence of LAT. Besides, the PALSE score was shown to accurately predict the presence of LA thrombus and SEC both in combination or separately. Patients with a PALSE score lower than 1 did not have thrombus or SEC on TEE. In contrast, CHA₂DS₂VASc did not demonstrate satisfactory results in terms of predicting the thromboembolic milieu.

The evaluation of the thromboembolic risk in AF remains the cornerstone of patient management. In current practice, clinical risk scores such as CHADS₂ (congestive heart failure, hypertension, diabetes, age ≥75 years, history of stroke or transient ischemic attack) and its more comprehensive variant, CHA₂DS₂VASc, predict the 1-year thromboembolic risk and are routinely used in decision-making concerning anticoagulant therapy. However, in the setting of the thromboembolic milieu, these risk scores seem to provide controversial data, which precludes their routine use. The prediction of the thromboembolic milieu may provide additional information beyond traditional risk scores in the evaluation of the thromboembolic risk in patients with AF.

Left atrial thrombus and SEC are well-known manifestations of the thromboembolic milieu in AF patients. They are caused by different pathological conditions and interrelated anatomical, hemodynamic, and biological factors, such as decreased blood flow velocity as well as increased blood viscosity and coagulopathy. Therefore, the evaluation of the thromboembolic risk should account for all these conditions in a more comprehensive manner.

In contrast to traditional risk scores depending on the cumulative thromboembolic risk, those depending on the presence of the thromboembolic milieu may provide better identification of high-risk patients. Current literature
suggests that patients with a visible thrombus or SEC in the LA are at higher thromboembolic risk. Therefore, assessing the thromboembolic risk on the basis of the thromboembolic milieu may offer a more robust approach to the management of AF.

Although TEE is the gold standard for thrombus and SEC detection, this procedure is semi-invasive and costly and is associated with considerable risks such as trauma, vagal and allergic reactions, hypotension, or anesthetic reactions. Because of these limitations, TEE cannot be performed in some patients. Therefore, the noninvasive identification of the thromboembolic milieu may be beneficial in some cases.

In accordance with previous research, our study demonstrated that the CHA$_2$DS$_2$VASc score does not seem to be useful for identification of the thromboembolic milieu in patients with paroxysmal AF. Several mechanisms may explain this finding. First, the CHA$_2$DS$_2$VASc score includes a wide range of stroke risk factors other than the thromboembolic milieu including atherosclerotic process. This heterogeneity may reduce the usefulness of this score in the identification of the thromboembolic milieu. In contrast, the PALSE score directly takes a picture of the left atrium at the moment of TEE representing the thromboembolic risk. Second, the CHA$_2$DS$_2$VASc score includes the general patient risk profiles, which may be inadequate for LA thrombus and/or SEC identification. The inclusion of biochemical and echocardiographic data in addition to general risk profiles in the PALSE score may enhance the discriminatory value of the risk model and provide a more detailed insight. In our study, of the 259 patients with a CHA$_2$DS$_2$VASc score lower than 2, 9.3% had LA thrombus and/or SEC. On the other hand, none of the patients with a PALSE score lower than 1 had SEC or thrombus. Therefore, the PALSE score seems to be a better risk model, at least for the identification of patients with LA thrombus and/or SEC.

One of the main components of the PALSE score is the LA diameter. In line with previous studies, the presence of LA dilation with a cutoff value of 40 mm was found to be a significant predictor of the thromboembolic milieu. Considering the pathophysiology of the thromboembolic milieu, this result is not surprising. The enlargement of the LA is associated with low velocity, which predisposes to the development of the thromboembolic milieu. Moreover, the LA diameter can be a marker of AF burden. Therefore, the LA size should always be included in the decision-making process in patients with AF.

Another important component of the score is SPAP. We speculated that increased SPAP in patients with AF is a sign of increased LA pressure. In patients with nonvalvular AF, the markers of increased left ventricular filling pressure such as brain natriuretic peptide and Doppler-derived E'/e’ ratio were shown to be closely related with the thromboembolic milieu. Kishima et al investigated the predictors of the thromboembolic milieu in patients with acute stroke. They demonstrated that left ventricular hypertrophy, which is closely related to pulmonary capillary wedge pressure (PCWP) was significantly associated with left atrial thrombus and SEC. Similarly, Tabata et al indicated that elevated PCWP was associated with reduced LAA velocities. The invasive evaluation of loading conditions such as PCWP and direct measurements of pulmonary artery pressures may be difficult and has limited use in comprehensive clinical assessment. On the other hand, SPAP, which reflects a passive increase in LA pressure in patients with AF, is a simple and more feasible marker that can be included in routine clinical evaluation.

Reduced LVEF and older age are well-known risk factors for the thromboembolic milieu in patients with AF. However, the reported cutoff values for age were slightly higher than the cutoff of 60 years in our study. In our research, we found an association between plasma protein levels and LA thrombus and/or SEC. Considering its pathomechanism, SEC is thought to be a manifestation of red blood cell aggregation, arising from the interaction between red blood cell and plasma proteins, mainly fibrinogen, at low shear rates. In patients with stroke, Briley et al found that elevated plasma proteins reflecting increased blood viscosity, such as fibrinogen and gamma globulin, were associated with SEC formation unlike the previously reported blood markers such as hematocrit, white blood cell count, and platelet levels. In accordance with their results, we did not observe any associations between the thromboembolic milieu and hematocrit, white blood cell and platelet counts, or albumin levels.

Plasma D-dimer levels and von Willebrand factor were also reported to be associated with SEC. To our knowledge, our study is the first to investigate the relationship between total protein levels and the thromboembolic milieu. We hypothesized that increased plasma levels of total protein might be a simple biomarker of increased blood viscosity and thus of a procoagulant state. Blood viscosity is the primary component of the Virchow triad; however, it is usually neglected because of the difficulties in measurement that requires specific equipment and provides variable results. The determination of the total protein level may be more feasible and may provide valuable information about the presence of the thromboembolic milieu.

The incidence of LA thrombus and/or SEC in our study was slightly higher (11.1%) than in previous research. The main reason for this discrepancy is that all our patients underwent TEE. Some previous studies included low-risk patients
in whom TEE was not performed, which might have resulted in a selection bias. Moreover, patients classified as low risk with traditional risk scores, in fact, had LA thrombus and/or SEC, which may predispose them to thromboembolic events if they do not receive anticoagulant therapy. Patients with AF require a more proactive and thorough approach. The PALSE score may provide additional risk classification in this specific population and may facilitate a more comprehensive patient management.

The aim of developing a novel risk model was to enable identification of patients who are categorized as low risk with classic risk models and therefore do not receive anticoagulant therapy, but who may actually have LA thrombus and/or SEC. In other words, “low-risk” patients may in fact not be at low risk. In view of this aim, the strength of our study is that all patients with nonvalvular AF had undergone TEE irrespective of their thromboembolic risk.

Another important aspect of our study is that the parameters included in the PALSE score (LA size, LV systolic dysfunction, age, and SPAP) are predictors of AF recurrence after catheter ablation. In addition to thrombogenicity, these parameters also seem to reflect the progression of AF in atrial tissue. However, prospective trials are needed to assess the usefulness of the PALSE score for predicting AF recurrence.

**Limitations** As our study had a cross-sectional design, follow-up data on thromboembolic events were unavailable. A follow-up of at least 1 year would strengthen our results. Moreover, all our patients had paroxysmal AF, so the PALSE score should be validated in other AF types such as persistent or paroxysmal AF. As a single-center study, it was limited to our institution (a high-volume tertiary electrophysiology center) and thus represented only the patient profile of our country. Therefore, although the score has been validated internally, an external validation would be valuable. Another limitation is the lack of sufficient data on the flow velocity of the LAA in our patients. Previous echocardiographic studies revealed its importance in predicting the thrombogenic milieu and thus thromboembolic events. The inclusion of LAA velocity in the PALSE score might reveal some important mechanisms that could enhance our clinical knowledge. On the other hand, our aim in this study was to identify patients at high risk prior to TEE. Therefore, the addition of LAA velocity, which is measured by TEE, might reduce the usefulness of this risk score in a general patient population.

**Conclusions** In conclusion, in patients with paroxysmal AF, total protein level, LA diameter, SPAP, age, and LVEF were identified as independent predictors of the thromboembolic milieu. Our new risk model, the PALSE score, which is composed of these parameters, seemed to accurately predict the presence of the thromboembolic milieu. Further prospective studies are warranted to confirm our findings.

**ARTICLE INFORMATION**

**CONFLICT OF INTEREST** None declared.

**OPEN ACCESS** This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International License (CC BY-NC-ND 4.0), allowing third parties to download articles and share them with others, provided the original work is properly cited, not changed in any way, distributed under the same license, and used for non-commercial purposes only. For commercial use, please contact the journal office at kardiologiapolska@pikardio.pl.

**HOW TO CITE** Oszon Corin EM, Dobay MB, Corin MS, et al. A new risk model for the evaluation of the thromboembolic milieu in patients with atrial fibrillation: the PALSE score. Kardiol Pol. 2020; 78: 732-740. doi:10.33963/KP.15402

**REFERENCES**

1. Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006; 27: 949-953.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370-2375.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-988.
4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with FACTS. Russ J Cardiol. 2017; 7-86.
5. Black TW, Hopkins AF, Lee LC, Walsh WP. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol. 1991; 18: 398-404.
6. Leung DYC, Black TW, Cranney GB, et al. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1994; 24: 755-762.
7. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med. 1998; 128: 639-647.
8. Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998; 31: 1622-1626.
9. Willems HJ, Gómez-Marin O, Nelson K, et al. Correlation of CHADS2 and CHA2DS2‑VASc Scores with transesophageal echocardiography risk factors for thromboembolism in a multicenter United States population with nonvalvular atrial fibrillation. J Am Soc Echocardiogr. 2013; 26: 175-184.
10. Warsner K, Köbe J, Dechering D, et al. CHA2DS2‑VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. Clin Res Cardiol. 2013; 102: 139-144.
11. Mascioli G, Lucena E, Michelot F, et al. Severe spontaneous echo contrast/auricular thrombus in ‘nonvalvar’ AF: value of thromboembolic risk scores. Pacing Clin Electrophysiol. 2017; 40: 57-62.
12. Gardin JM, Adams DB, Douglas PS, et al. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography’s Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr. 2002; 15: 275-290.
13. Hahn RT, Abraham T, Adams MS, et al. Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr. 2013; 26: 921-964.
14. Sarit M, Armour AC, Arnaout MS, et al. Guidelines for the use of echocardiography in the evaluation of a cardiac source of embolism. J Am Soc Echocardiogr. 2016; 29: 1-42.
15. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18: 1440-1463.
16. Fadl D, Kolly RF, Fenley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994; 23: 961-969.
17. U O, Akalu M, Dogan M, et al. The CHA2DS2‑VASc score as a predictor of left atrial thrombus in patients with non-valvular atrial fibrillation. Med Prin Pract. 2014; 23: 234-238.
18. Aisinger RW, Koehler J, Pearce LA, et al. Pathophysiologic Correlates of Thromboembolism in Nonvalvar Atrial Fibrillation: II. Dense Spontaneous
Echocardiographic Contrast (The Stroke Prevention in Atrial Fibrillation [SPAF‑III]) Study). J Am Soc Echocardiogr. 1999; 12: 1088‑1096.

19 Ito T, Sowa M. Left atrial spontaneous echo contrast: relationship with clinical and echocardiographic parameters. Echo Res Pract. 2019; 6: R5‑R73.

20 Ito T, Sowa M, Kobashi A, et al. Integrated backscatter assessment of left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation: relationship with clinical and echocardiographic parameters. J Am Soc Echocardiogr. 2000; 13: 666‑673.

21 Black IV, Chesterman CN, Hopkins AP, et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1993; 21: 451‑457.

22 Manning WJ. Accuracy of transesophageal echocardiography for identifying left atrial thrombus: a prospective, intraoperative study. Ann Intern Med. 1995; 123: 817.

23 Kishina H, Mine T, Fukuura E, et al. Predictors of left atrial thrombi and spontaneous echocardiographic contrast in the acute phase after cardioembolic stroke in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2019; 28: 1571‑1577.

24 Hamatani Y, Ogawa H, Takabayashi K, et al. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Sci Rep. 2016; 6: 31042.

25 Providencia R, Boleto A, Tripp J, et al. Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters. Europe. 2012; 14: 36‑45.

26 Sanfilippo AJ, Abascal VM, Sheehan M, et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation. 1990; 82: 793‑797.

27 Yu GI, Che RZ, Kim HS, et al. Association between the N‑terminal plasma brain natriuretic peptide levels or elevated left ventricular filling pressure and thromboembolic risk in patients with non‑valvular atrial fibrillation. J Cardiol. 2016; 68: 110‑116.

28 Iwakura K, Okamura A, Košman Y, et al. Effect of elevated left ventricular diastolic filling pressure on the frequency of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2011; 107: 417‑422.

29 Chrispin J, Jain A, Soliman EZ, et al. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi‑Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014; 63: 2007‑2013.

30 Tabata T, Oki T, Fukuda N, et al. Influence of left atrial pressure on left atrial appendage flow velocity patterns in patients in sinus rhythm. J Am Soc Echocardiogr. 1996; 9: 857‑864.

31 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154: 1449.

32 Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. ACC Current Journal Review. 2001; 10: 20‑21.

33 Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor‑based approach. Chest. 2010; 137: 263‑272.

34 Black IV. Spontaneous echo contrast: where there’s smoke there’s fire. Echocardiography. 2000; 17: 373‑382.

35 Brilley DP, Giraud GD, Beamer NB, et al. Spontaneous echo contrast and hemorheologic abnormalities in cerebrovascular disease. Stroke. 1994; 25: 1564‑1569.

36 Hegpelt RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non‑rheumatic atrial fibrillation. Heart. 1997; 77: 407‑411.

37 Wan H, Wu S, Yang Y, et al. Plasma fibrin D‑dimer and the risk of left atrial thrombus: A systematic review and meta‑analysis. PLoS One. 2017; 12: e0172722.

38 Pignatelli P, Violi F, Pastori D. Integrated care management of patients with atrial fibrillation – far from optimal. Pol Arch Intern Med. 2020; 130: 176‑178.

39 Liżewska‑Springer A, Dąbrowska‑Kugacka A, Lewicka E, et al. Echocardiographic assessment in patients with atrial fibrillation (AF) and normal‑systolic left ventricular function before and after catheter ablation: if AF beats AF, does pulmonary vein isolation terminate the vicious circle? Cardiol J. 2020; 27: 126‑135.

40 Liżewska‑Springer A, Dąbrowska‑Kugacka A, Lewicka E, et al. Bilateral strain as a new predictive marker of successful pulmonary vein ablation in patients with atrial fibrillation and preserved left ventricular function. Kardiol Pol. 2019; 77: 471‑474.

41 Handke M, Harloff A, Hetzel A, et al. Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echoclartrast and thrombus formation–a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr. 2005; 18: 1366‑1372.